Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Combining two immunotherapies into a single treatment found to be more effective

Combining two immunotherapies into a single treatment found to be more effective

Reactivation of divergent signaling pathways can be leveraged to enhance cancer treatment

Reactivation of divergent signaling pathways can be leveraged to enhance cancer treatment

Researchers identify specific target sites for DNA methylases

Researchers identify specific target sites for DNA methylases

GlobalData: Hematology tests can be a prognostic marker to predict severity of COVID-19 patients

GlobalData: Hematology tests can be a prognostic marker to predict severity of COVID-19 patients

Experimental therapy slows zika replication and prevents microcephaly in mice

Experimental therapy slows zika replication and prevents microcephaly in mice

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

Rare inherited mutation in TP53 gene confers risk of multiple cancers

Rare inherited mutation in TP53 gene confers risk of multiple cancers

Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

Cancer drug could help inhibit adenovirus infection

Cancer drug could help inhibit adenovirus infection

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

New cancer vaccine shows promising signs in preclinical studies

New cancer vaccine shows promising signs in preclinical studies

Mapping immune landscape of hematological malignancies may help improve cancer therapies

Mapping immune landscape of hematological malignancies may help improve cancer therapies

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

Researchers create new tool to identify cancer-causing mutations lurking in 98% of the genome

Researchers create new tool to identify cancer-causing mutations lurking in 98% of the genome

Latest findings put Benson Viscometers at the forefront of Covid-19 fight

Latest findings put Benson Viscometers at the forefront of Covid-19 fight

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Salk Institute expands research to find treatments and cures for COVID-19

Salk Institute expands research to find treatments and cures for COVID-19

Engineered immune cells attack solid-tumor cancer cells from humans and mice

Engineered immune cells attack solid-tumor cancer cells from humans and mice

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.